Medtronic Strikes Again, This Time With AVE

Medtronic has acquired Arterial Vascular Engineering Inc., capping a string of large, impressive deals that should help build major businesses in important new areas. With the AVE deal, Medtronic has in the last year alone spent almost $8 billlion to acquire five companies.

As they say in New York, when the going gets tough, the tough go shopping. Over the past several years, Medtronic Inc. had quietly stood back while each of several cardiovascular device rivals grabbed headlines with high-profile acquisitions. First it was Johnson & Johnson with its hostile bid for Cordis Corp. [See Deal].

Medtronic hasn't been idle exactly. But the deals it did—for Target rival Micro Interventional Systems Inc. for example

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.